死亡盒直酶家族蛋白质:在消化系统癌症中新兴的标,以及在向药物开发中的进展
Xiaochao Ma1, Tianyu Lu1, Yue Yang1
1Department of Thoracic Surgery, Organ Transplantation Center, the First Hospital of Jilin University, 1 Ximin Street, ChangchunJilin, 130021, China.
Journal of translational medicine
|December 20, 2024
概括
死亡盒螺旋酶蛋白在RNA代谢中至关重要,并在消化系统癌症中发挥关键作用. 本综述探讨了它们作为食道和胃肠道瘤的治疗点的功能和潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 消化系统癌症,包括食道和胃肠道瘤,是全球严重的健康负担,尽管治疗方面取得了进展,但预后不佳.
- 死亡盒螺旋酶 (DDX) 蛋白质是必不可少的RNA螺旋酶,参与许多RNA代谢过程,对细胞功能至关重要.
- DDX蛋白质的失调与各种癌症的发病和进展有关.
研究的目的:
- 综合审查DEAD-box酶家族蛋白质在消化系统癌症的发生,发展和进展中的作用.
- 讨论在食道和胃肠道恶性瘤中向DDX蛋白的潜在临床应用和治疗策略.
- 突出这一领域最近的进展和未来的研究方向.
主要方法:
- 文献综述和对现有研究的综合 DEAD-box 螺旋酶和消化系统癌症.
- 分析DDX家族蛋白在RNA代谢中的功能.
- 检查DDX蛋白与临床因素,癌症扩散,迁移,入侵和消化系统癌症的信号通路之间的关联.
主要成果:
- 死亡盒酶蛋白在食道和胃肠道癌症的发展和进展中起着重要作用.
- DDX蛋白质通过各种信号通路影响癌细胞的增殖,迁移和入侵.
- 特定的DDX家族成员与临床参数呈现相关性,表明它们的预后和诊断潜力.
结论:
- 死亡盒酶蛋白是消化系统癌症的关键调节者,为新的治疗干预提供了有前途的标.
- 向DDX家族蛋白质为改善食道和胃肠道癌症患者治疗结果的潜在策略.
- 对DDX蛋白质的特定作用和抑制策略进行进一步的研究是必要的.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
DNA Helicases
21.1K
DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
21.1K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K


